This Article Full Text Full Text (PDF) CME: Take the course for this article: HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and I... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pérez-Soler, R. Articles by Leyden, J. Search for Related Content PubMed PubMed Citation Articles by Pérez-Soler, R. Articles by Leyden, J.

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum

^a Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA; ^b Institut Claudius Regaud, Toulouse, France; ^c Memorial Sloan-Kettering Cancer Center, New York, New York, USA; ^d University of Colorado Health Sciences Center, Denver, Colorado, USA; ^e The Rockefeller University, Dermatology Laboratory, New York, New York, USA; ^f Servicio Oncologiá Médica, Hospital General Universitario Alicante, Alicante, Spain; ^g Asklepios Fachkliniken, Gauting-Munich, Germany; ^h Massachusetts General Hospital, Boston, Massachusetts, USA; ⁱ Divisione Oncologia Medica Falck, Ospedale Niguarda Cá Granda, Milano, Italy; ^j Centre d’Oncologie, CHUM Campus Notre-Dame, Montreal, Quebec, Canada; ^k University of Pennsylvania Hospital, Malvern, Pennsylvania, USA

Correspondence: Román Pérez-Soler, M.D., Department of Oncology, Hofheimer 100, Montefiore Medical Center/Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA. Telephone: 718-920-4001; Fax: 718-798-7474; e-mail: rperezso{at}montefiore.org

Skin rash associated with HER1/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1/EGFR inhibitors attended the HER1/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.

Key Words. HER1/EGFR • Rash • Adverse event • Survival • NSCLC • Tyrosine kinase inhibitor • Monoclonal antibody

This article has been cited by other articles:

				R. N. Schwartz Management of early and advanced colorectal cancer: Therapeutic issues Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S8 - S14. [Abstract] [Full Text] [PDF]

				A. R. Tan, S. M. Steinberg, A. L. Parr, D. Nguyen, and S. X. Yang Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment Ann. Onc., January 1, 2008; 19(1): 185 - 190. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 28 - 36. [Abstract] [Full Text] [PDF]

				A. Pivarcsi, A. Muller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression PNAS, November 27, 2007; 104(48): 19055 - 19060. [Abstract] [Full Text] [PDF]

				B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921. [Abstract] [Full Text] [PDF]

				T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management Oncologist, May 1, 2007; 12(5): 610 - 621. [Abstract] [Full Text] [PDF]

				C. S. Viele Managing oral chemotherapy: The healthcare practitioner's role Am. J. Health Syst. Pharm., May 1, 2007; 64(9_Supplement_5): S25 - S32. [Abstract] [Full Text] [PDF]

				H. H. Schiffer, E. C. Reding, S. R. Fuhs, Q. Lu, F. Piu, S. Wong, P.-L. H. Littler, D. M. Weiner, W. Keefe, P. K. Tan, et al. Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer Mol. Pharmacol., February 1, 2007; 71(2): 508 - 518. [Abstract] [Full Text] [PDF]

				S. S. Mitra and R. Simcock Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field J. Clin. Oncol., June 1, 2006; 24(16): e28 - e29. [Full Text] [PDF]

				D. G.P. Allan Nimotuzumab: Evidence of Clinical Benefit Without Rash Oncologist, October 1, 2005; 10(9): 760 - 761. [Full Text] [PDF]